The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Cancer Research

Volumn 66, Issue 2, 2006, Pages 951-959

  Zhang, Ling Hua ^a   Wu, Lei ^a   Raymon, Heather K ^a   Chen, Roger S ^a   Corral, Laura ^a   Shirley, Michael A ^a   Narla, Rama Krishna ^a   Gamez, Jim ^a   Muller, George W ^a   Stirling, David I ^a   Bartlett, J Blake ^a   Schafer, Peter H ^a   Payvandi, Faribourz ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CC 5079; CHECKPOINT KINASE 1; COLCHICINE; PACLITAXEL; PHOSPHODIESTERASE IV INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; DEPOLYMERIZATION; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MICROTUBULE ASSEMBLY; MOLECULAR MECHANICS; MULTIDRUG RESISTANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; NEOPLASMS; NITRILES; TRANSPLANTATION, HETEROLOGOUS; TUBULIN; TUBULIN MODULATORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31544451252     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2083     Document Type: Article

References (37)

1. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Cane Agents 2002;2:1-17.
2. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44:355-61.
3. Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat 2001;4:392-401.
4. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001;1:370-7.
5. Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607-12.
6. Michiel DF, Oppenheim JJ. Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 1992;3:3-15.
7. Montserrat E. Chronic lymphoproliferative disorders. Curr Opin Oncol 1997;9:34-41.
8. Hamilton K, Clair EW. Tumour necrosis factor-α blockade: a new era for effective management of rheumatoid arthritis. Expert Opin Pharmacother 2000;1: 1041-52.
9. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999;20:538-40.
10. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses. Proc Natl Acad Sci U S A 2002;99: 7628-33.
11. Shan J, Mason JM, Yuan L, et al. Rab6c, a new member of the rab gene family, is involved in drug resistance in MCF7/AdrR cells. Gene 2000;257:67-75.
12. Uchiyama-Kokubu N, Watanabe T. Establishment and characterization of Adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs 2001;12:769-79.
13. Zhang LH, Longley RE. Induction of apoptosis in mouse thymocytes by microcolin A and its synthetic analog. Life Sci 1999;64:1013-28.
14. Isbrucker RA, Gunasekera SP, Longley RE. Structure-activity relationship studies of discodermolide and its semisynthetic acetylated analogs on microtubule function and cytotoxicity. Cancer Chemother Pharmacol 2001;48:29-36.
15. Tahir SK, Kovar P, Rosenberg SH, Ng SC. Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques 2000; 29:156-60.
16. Marriott JB, Westby M, Cookson S, et al. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-α production. J Immunol 1998;161:4236-43.
17. DiSanto ME, Heaslip RJ. Identification and stabilization of large molecular weight PDE-IVs from U937 cells. Biochem Biophys Res Commun 1993;197: 1126-31.
18. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17: 1061-70.
19. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 2000;25:1-6.
20. Scatena CD, Stewart ZA, Mays D, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998;273:30777-84.
21. 2-M transition by p53. Oncogene 2001;20:1803-15.
22. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997;91:443-6.
23. Nitiss JL. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr Opin Investig Drugs 2002;3:1512-6.
24. Zhang LH, Wu L, Shirley MA, et al. Novel potent class of small molecules, inhibitors of tubulin polymerization and TNF-α production with anti-tumor activity. Proc Am Assoc Cancer Res 2003;44:LB-30.
25. Griffloen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-68.
26. Miller WJ, Kayton ML, Patton A, et al. A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay. J Transl Med 2004;2:4.
27. Ling YH, Tornos C, Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 1998;273:18984-91.
28. Zhang LH, Youn HD, Liu JO. Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFκB-dependent activation of p53. J Biol Chem 2001;276:43534-40.
29. Harding A, Giles N, Burgess A, Hancock JF, Gabrielli BG. Mechanism of mitosis-specific activation of MEK1. J Biol Chem 2003;278:16747-54.
30. Nam NH, Parang K. Current targets for anticancer drug discovery. Curr Drug Targets 2003;4:159-79.
31. Drukman S, Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents [review]. Int J Oncol 2002;21:621-8.
32. Marko D, Pahlke G, Merz KH, Eisenbrand G. Cyclic 3′,5′- nucleotide phosphodiesterases: potential targets for anticancer therapy. Chem Res Toxicol 2000; 13:944-8.
33. Ogawa R, Streiff MB, Bugayenko A, Kato GJ. Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21 (WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells. Blood 2002;99: 3390-7.
34. Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma 2000;37:39-51.
35. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 1998;92:2484-94.
36. Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy-a critical review. Can J Gastroenterol 2001; 15:376-84.
37. Szlosarek PW, Balkwill FR. Tumour necrosis factor α: a potential target for the therapy of solid tumours. Lancet Oncol 2003;4:565-73.